Summary
CATX Chart
People also search for
Are Medical Stocks Lagging Perspective Therapeutics, Inc. (CATX) This Year?
Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Perspective Therapeutics (CATX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?
Here is how Perspective Therapeutics (CATX) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
Perspective Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 34 | $131.76 | $102 | -$29.76 | -22.59% |
| NA Nizar Araji National Bank Of Canada /FI/ | 654 | $2,102.1 | $1,962 | -$140.1 | -6.66% |
| BG Bart Gancher Intech Investment Management LLC | 24,370 | $65,995.3 | $73,110 | $7,114.7 | 10.78% |
| AB Anthony Bruccoleri Equitable Holdings Inc. | 10,000 | $34,100 | $32,000 | -$2,100 | -6.16% |
 Joseph Castro Nuveen LLC | 336,817 | $1.16M | $1.01M | -$148,199.45 | -12.79% |
Perspective Therapeutics Inc. (CATX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Perspective Therapeutics Inc. ever had a stock split?
Perspective Therapeutics Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Johan Spoor CEO | AMEX Exchange | 46489V302 CUSIP |
| US Country | 165 Employees | - Last Dividend | 17 Jun 2024 Last Split | - IPO Date |
Overview
Perspective Therapeutics, Inc., operating alongside its subsidiaries, is at the forefront of developing precision-targeted alpha therapies (TAT) dedicated to the oncology field, with a focus on treating cancer patients suffering from various tumor types, including metastatic disease. The company engages in the discovery, design, and development of its pioneering program candidates, striving to offer new therapeutic possibilities for cancer patients. Formerly known as Isoray, Inc., Perspective Therapeutics changed its name in February 2022, marking a new era in its journey since its inception in 1998. Based in Seattle, Washington, Perspective Therapeutics has established itself as a notable entity in the biotechnology sector, particularly in delivering innovative cancer treatment solutions.
Products and Services
- VMT-a-NET
Currently in Phase 1/2a clinical trials, VMT-a-NET represents Perspective Therapeutics’ commitment to advancing cancer treatment. This program is targeting patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors. Specifically, it caters to those patients who have not previously received peptide-targeted radiopharmaceutical therapy, including alternatives like Lutathera, a beta-emitting therapy. VMT-a-NET stands out as a pivotal development in targeting specific cancer types with precision.
- VMT01
VMT01 is in the spotlight for its Phase 1/2a clinical trials targeting the second-line or later treatment of patients with metastatic melanoma, emphasizing those with progressive melanocortin 1 receptor (MC1R) positive tumors. This innovative approach highlights Perspective Therapeutics' efforts in expanding the range of effective treatments for different cancer types, especially for conditions that have limited treatment options.
In its pursuit of excellence in oncology, Perspective Therapeutics has forged a significant clinical trial collaboration with Bristol Myers Squibb. This partnership focuses on evaluating the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. Such collaborations underscore Perspective Therapeutics’ role in the broader ecosystem of cancer research, aiding in the development of groundbreaking therapies.
